Last edition
News about Global Pharma
Eli Lilly Appoints New Executives, Expands Senior Leadership Roles to Drive Next Phase of Growth
Eli Lilly has appointed Carole Ho and Adrienne Brown to lead the company’s expansion in neuroscience and immunology, while also broadening the responsibilities of Daniel Skovronsky and Jacob Van Naarden to further strengthen its leadership team.
Global Pharma | 07/11/2025 | By Dineshwori | 1338
Acumed Expands CMF Capabilities with Acquisition of TECHFIT Digital Surgery Assets
Through the deal, Acumed gains full ownership of TECHFIT Digital Surgery's proprietary technologies, including its digital surgical planning and reconstruction platform.
Global Pharma | 06/11/2025 | By Dineshwori | 525
Dynavax, Vaxart Enter Exclusive Global License Agreement for Novel Oral COVID-19 Vaccine
Under the terms of the agreement, Dynavax will receive exclusive, worldwide rights to develop and commercialise oral COVID-19 vaccines based on Vaxart’s delivery platform.
Global Pharma | 06/11/2025 | By Dineshwori | 1409
WHO and Bayer Renew Partnership to Combat NTDs
The World Health Organization (WHO) and Bayer AG have renewed their partnership to combat Chagas disease, sleeping sickness, and taeniasis, with Bayer pledging USD 9.45 million to support WHO’s efforts through 2030.
Global Pharma | 06/11/2025 | By Dineshwori | 366
Novo Nordisk Submits Updated Proposal to Acquire Metsera in Multi-Billion-Dollar Deal
Novo Nordisk has confirmed that it has submitted an updated, unsolicited proposal to acquire Metsera, which has been declared superior by Metsera’s board of directors.
Global Pharma | 06/11/2025 | By Dineshwori | 361
FDA Grants ODD to Leukogene Therapeutics' M2T-CD33 (LTI-214) for Treating Acute Myeloid Leukemia
The US FDA has granted ODD to Leukogene Therapeutics’ M2T-CD33 (LTI-214) for the treatment of Acute Myeloid Leukemia (AML). The designation highlights the pressing need for new treatment options and acknowledges LTI-214’s potential as a novel and targeted therapy for this aggressive form of blood cancer.
Global Pharma | 05/11/2025 | By Dineshwori | 358
Relonchem Gets MHRA Nod for Exemestane 25 mg Tablets
Exemestane by Relonchem, a subsidiary of Markans Pharma, is an aromatase inhibitor used in the treatment of hormone-dependent breast cancer in postmenopausal women. The approval marks another milestone in Marksans Pharma’s strategy to expand its oncology portfolio and strengthen its presence in the UK and European markets.
Global Pharma | 05/11/2025 | By Dineshwori | 333
Eli Lilly has announced plans to invest USD 3 billion in a new manufacturing facility in Katwijk, the Netherlands, to expand its global capacity for producing oral medicines and strengthen its supply chain network.
Global Pharma | 04/11/2025 | By Dineshwori | 413
Merz Aesthetics Unveils Ergonomically Designed Belotero Syringe for Enhanced Precision and Comfort
The syringe has been engineered to provide greater precision, comfort, and control, enhancing the overall treatment experience for both practitioners and patients. It will first be introduced in Europe before a phased rollout across global markets.
Global Pharma | 04/11/2025 | By Darshana | 282
AIxMed and PathNet Partner to Advance Digital Pathology with AI-Driven Urine Cytology
AIxMed has partnered with PathNet to advance digital pathology through its AIxURO solution, an AI-powered platform designed to enhance the analysis of non-invasive urine cytology samples. The collaboration aims to boost diagnostic accuracy and streamline workflows in bladder cancer detection.
Global Pharma | 04/11/2025 | By Dineshwori | 366
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy